Page last updated: 2024-12-07

pd 123177

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

PD 123177: nonpeptide angiotensin AII-2 inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID114899
CHEMBL ID535139
CHEMBL ID1188080
CHEBI ID79978
SCHEMBL ID7060144
MeSH IDM0181874

Synonyms (28)

Synonym
1-[(4-amino-3-methylphenyl)methyl]-5-[2,2-di(phenyl)acetyl]-6,7-dihydro-4h-imidazo[5,4-d]pyridine-6-carboxylic acid
gtpl596
PDSP2_000643
pd 123177
114785-12-5
PDSP2_000579
PDSP1_000649
PDSP1_000648
PDSP1_000582
pd123177
exp 655
pd-123177
CHEMBL535139 ,
L000467
1-[(4-amino-3-methylphenyl)methyl]-5-(2,2-diphenylacetyl)-6,7-dihydro-4h-imidazo[4,5-c]pyridine-6-carboxylic acid
CHEMBL1188080
exp-655
1-((4-amino-3-methylphenyl)methyl)-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1h-imidazo(4,5c)pyridine-6-carboxylic acid
1h-imidazo(4,5-c)pyridine-6-carboxylic acid, 1-((4-amino-3-methylphenyl)methyl)-5-(diphenylacetyl)-4,5,6,7-tetrahydro-
bdbm50370405
CHEBI:79978 ,
SCHEMBL7060144
1-(4-amino-3-methylphenyl)methyl-5-diphenylacetyl-4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine-6-carboxylic
1-[(4-amino-3-methylphenyl)methyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine-6-carboxylic acid
DTXSID90921497
1-(4-amino-3-methylbenzyl)-5-(2,2-diphenylacetyl)-4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine-6-carboxylic acid
Q27088257
AKOS040749136

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" caused dose-dependent parallel rightward shifts of the dose-response curves (DBP and LVdP/dtmax) without altering the maximal responses to AII."( Effect of various angiotensin receptor antagonists on cardiovascular responses to angiotensin II in pithed rats.
Pfaffendorf, M; van Zwieten, PA; Zhang, J, 1994
)
0.29
" Losartan, but not PD123177, shifted the dose-response curves for AII to the right in a parallel manner."( Hemodynamic effects of angiotensin II and the influence of angiotensin receptor antagonists in pithed rabbits.
Pfaffendorf, M; van Zwieten, PA; Zhang, J, 1995
)
0.29
" Losartan but not PD123177 caused parallel rightward shifts of the dose-response curve of angiotensin II for dP/dtmax in the aortic blood pressure controlled pithed rat without altering the maximal response."( Positive inotropic action of angiotensin II in the pithed rat.
Pfaffendorf, M; van Zwieten, PA; Zhang, J, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diarylmethaneAny compound containing two aryl groups connected by a single C atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1346291Rat AT2 receptor (Angiotensin receptors)1989Biochemical and biophysical research communications, Nov-30, Volume: 165, Issue:1
Identification of angiotensin II receptor subtypes.
AID1346291Rat AT2 receptor (Angiotensin receptors)1993Regulatory peptides, Mar-19, Volume: 44, Issue:2
Regulated expression of angiotensin II (AT2) binding sites in R3T3 cells.
AID1346291Rat AT2 receptor (Angiotensin receptors)1990Molecular pharmacology, Mar, Volume: 37, Issue:3
Two distinct angiotensin II receptor binding sites in rat adrenal revealed by new selective nonpeptide ligands.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (136)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.74)18.7374
1990's124 (91.18)18.2507
2000's9 (6.62)29.6817
2010's2 (1.47)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.13 (24.57)
Research Supply Index4.96 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews9 (6.34%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other133 (93.66%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]